Zanubrutinib summary slide.JPG (31.98 kB)

Zanubrutinib: First Approval

Download (31.98 kB)
online resource
posted on 16.01.2020 by Yahiya Y. Syed
Compliance with Ethical Standards

Funding The preparation of this review was not supported by any external funding.

Conflict of interest  During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Syed is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found here

Abstract
Zanubrutinib (Brukinsa®), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based on overall response rate (ORR) seen in phase II and I/II clinical trials. This article summarizes the milestones in the development of zanubrutinib leading to this first approval for the treatment of MCL.

© Springer Nature Switzerland AG 2019

History

Exports

Read the peer-reviewed publication

Logo branding

Categories

Exports